About Florida Cancer Specialists & Research Institute, LLC: (Homepage)
Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.
How Do Community Oncologists View the Use of MRD Testing?
October 1st 2024Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease (MRD) negativity testing in an abstract presented at the International Myeloma Society 21st Annual Meeting & Exposition.
Read More
Best Practices That Target Selinexor Treatment Improve MM-Related Outcomes
January 29th 2024Patient survival and such treatment-related outcomes as time to treatment failure and treatment duration improved following implementation of a best practices program that focused on selinexor administration for multiple myeloma (MM), with implications for other anticancer medications.
Read More
ASH Abstracts Showcase Effective Treatments for MM, CLL, FL
January 20th 2024Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).
Read More
Top 5 Content From Institute for Value-Based Medicine® Events in 2023
December 27th 2023In 2023, there were 18 oncology and 7 population health Institute for Value-Based Medicine® events cohosted with organizations such as Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.
Read More
Dr Lucio Gordan Discusses Updated Guidelines Addressing 1q Abnormalities in Multiple Myeloma
October 27th 2023Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Dr Gustavo Fonseca on Key Takeaways From an FCS Analysis on Clinical Trial Enrollment
August 19th 2023Gustavo Fonseca, MD, FACP, physician director of clinical research, Florida Cancer Specialists & Research Institute (FCS), discusses the results from a late phase complexity analysis on barriers to clinical trials regarding biopsy requirements.
Watch
Dr Jennifer Gass Provides an Overview of FCS' Next-Generation Sequencing Laboratory
August 16th 2023Jennifer Gass, PhD, FACMG, associate director, Genetics Laboratory, Florida Cancer Specialists & Research Institute, discusses the recent Genetics Laboratory, which focuses on next-generation sequencing (NGS) testing in oncology care.
Watch
Dr Judy Wang on the Potential of CLN-619 for the Treatment of Solid Tumors
June 5th 2023Judy Wang, MD, medical oncologist and clinical trials investigator at Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, discussed the mechanism of action and rationale for studying CLN-619, an anti-MICA/B antibody, with and without pembrolizumab in patients with solid tumors.
Watch
Florida Cancer Specialists Highlights Role in Development of Polatuzumab Vedotin Plus R-CHP in DLBCL
May 10th 2023Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.
Read More
Dr Lucio Gordan Outlines the Treatment Paradigm for KRAS-Positive NSCLC
February 6th 2023Being able to treat patients with non–small cell lung cancer (NSCLC) and a KRAS mutation with sotorasib has been exciting, and now there’s another drug available with the approval of adagrasib at the end of 2022, explained Lucio Gordan, MD, of Florida Cancer Specialists & Research Institute.
Read More